Partum Biopharma is a biotech research company founded in 2018 and based in Irvine, California, United States. It is a research-based company, focusing entirely on finding a novel cost-effective alternative transfecting agent and therapeutic delivery solution using a specifically designed peptide system, through which small interfering RNA (siRNA) will be successfully delivered into the cell.

​

Although the delivery of siRNA to the cytoplasm of the cells is challenging, Partum Biopharma is engaged in the development of an efficient cyclic peptide platform technology that is expected to be used for both in vitro and in vivo delivery systems. As a part of its current accomplishments, the company was also able to develop transfection of breast cancer MDA-MB-231 cells with STAT3 and SRC siRNA.

​

Partum Biopharma is collaborating with researchers on its novel transfection technology to facilitate delivery of siRNA into diverse groups of cell lines successfully without causing any harm to the cell.